Theravance Pushes On With Gastroparesis Candidate Amid Mixed Data
Theravance is working out what to do next with its investigational drug for gastroparesis after it produced mixed data in a Phase IIb trial in this underserved indication.
You may also be interested in...
Company develops selective JAK inhibitors for IBD and pulmonary disease that are intended to clear the body before systemic side effects can occur. It also has a drug candidate for NOH that analysts think is underappreciated.
Theravance and the private Italian pharmaceutical group Alfa Wassermann have signed an exclusive development and commercialisation agreement worth up to $63.5 million plus royalties from sales for the US company's oral 5-HT4 agonist velusetrag (TD-5108) as a treatment for gastrointestinal motility disorders.
Last week, the Swiss major gave a glimpse into the next wave of innovation coming out of its labs in key areas such as osteoarthritis, pancreatic cancer and food allergy. Scrip has been taking a detailed look at the highlights.